{
  "ticker": "APLS",
  "company_name": "Apellis Pharmaceuticals, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT03593200",
      "title": "A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "PNH",
      "start_date": "2018-08-16",
      "completion_date": "2019-10-22",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02503332",
      "title": "Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Geographic Atrophy",
      "start_date": "2015-09-24",
      "completion_date": "2018-01-17",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03465709",
      "title": "Pegcetacoplan (APL-2) in Neovascular AMD",
      "status": "TERMINATED",
      "phase": "PHASE1, PHASE2",
      "condition": "Neovascular Age-related Macular Degeneration",
      "start_date": "2018-02-14",
      "completion_date": "2019-04-05",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02264639",
      "title": "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "start_date": "2015-02-23",
      "completion_date": "2018-10-22",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT05148299",
      "title": "A Study of Pegcetacoplan for Patients With Transplant-associated Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Transplant-Associated Thrombotic Microangiopathy",
      "start_date": "2022-02-01",
      "completion_date": "2024-12-08",
      "enrollment": 0,
      "sponsor": "Swedish Orphan Biovitrum"
    },
    {
      "nct_id": "NCT03453619",
      "title": "Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease",
      "start_date": "2018-02-26",
      "completion_date": "2023-08-26",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT02588833",
      "title": "Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Paroxysmal Nocturnal Hemoglobinuria",
      "start_date": "2015-12-01",
      "completion_date": "2019-08-26",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04085601",
      "title": "A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Paroxysmal Nocturnal Hemoglobinuria",
      "start_date": "2019-08-27",
      "completion_date": "2021-06-23",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT04402060",
      "title": "A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome",
      "start_date": "2020-05-28",
      "completion_date": "2021-02-13",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    },
    {
      "nct_id": "NCT03525600",
      "title": "Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration",
      "status": "COMPLETED",
      "phase": "PHASE3",
      "condition": "Geographic Atrophy",
      "start_date": "2018-08-31",
      "completion_date": "2022-06-20",
      "enrollment": 0,
      "sponsor": "Apellis Pharmaceuticals, Inc."
    }
  ],
  "summary": {
    "total_trials": 30,
    "by_phase": {
      "PHASE2": 9,
      "PHASE1, PHASE2": 2,
      "PHASE1": 4,
      "PHASE3": 10,
      "NA": 1,
      "": 3,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "COMPLETED": 18,
      "TERMINATED": 2,
      "UNKNOWN": 1,
      "NOT_YET_RECRUITING": 2,
      "RECRUITING": 2,
      "APPROVED_FOR_MARKETING": 1,
      "ACTIVE_NOT_RECRUITING": 4
    },
    "active_trials": 6,
    "completed_trials": 18,
    "conditions": [
      "Age-Related Macular Degeneration",
      "Amyotrophic Lateral Sclerosis, Motor Neuron Disease",
      "C3G, IC-MPGN, C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Complement 3 Glomerulonephritis, Dense Deposit Disease, DDD, Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",
      "C3G, IC-MPGN, Renal Transplant, Complement 3 Glomerulopathy, Complement 3 Glomerulopathy (C3G), Dense Deposit Disease (DDD), Membranoproliferative Glomerulonephritis, Membranoproliferative Glomerulonephritis (MPGN), Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), C3 Glomerulopathy, C3 Glomerulonephritis, Complement 3 Glomerulonephritis",
      "COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome",
      "Delayed Graft Function, End Stage Renal Disease, Deceased Donor Kidney Transplant",
      "FSGS",
      "Geographic Atrophy",
      "Geographic Atrophy Secondary to Age-related Macular Degeneration",
      "IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease",
      "Neovascular Age-Related Macular Degeneration",
      "Neovascular Age-related Macular Degeneration",
      "PNH",
      "Paroxysmal Nocturnal Hemoglobinuria",
      "Paroxysmal Nocturnal Hemoglobinuria (PNH)",
      "Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Hemoglobinuria",
      "Transplant-Associated Thrombotic Microangiopathy",
      "Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:41.882610",
    "search_query": "Apellis Pharmaceuticals, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Apellis+Pharmaceuticals,+Inc."
  }
}